Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01962948 · ClinicalTrials.gov registry record · Phase 1
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01962948 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT01962948, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of ganetespib when given together with paclitaxel and to see how well they work in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel and ganetespib may be an effective treatment for ovarian, fallopian tube, or primary peritoneal cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG paclitaxel
- DRUG ganetespib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-10-09 |
| Est. Completion | 2018-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01962948
The ClinicalTrials.gov registry entry for NCT01962948 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01962948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01962948 about?
NCT01962948 is a clinical study titled "Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This phase I/II trial studies the side effects and best dose of ganetespib when given together with paclitaxel and to see how well they work in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different wa...
What is the current status of trial NCT01962948?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-10-09. Estimated completion is 2018-07-06.
What interventions are being tested in trial NCT01962948?
The interventions under investigation include: laboratory biomarker analysis (OTHER), paclitaxel (DRUG), ganetespib (DRUG).
Who is sponsoring clinical trial NCT01962948?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.